- 1 Novel protein markers of androgen activity in humans: proteomic
- 2 study of plasma from young chemically castrated men.
- 3 Aleksander Giwercman^{1*}, K Barbara Sahlin^{2,3*}, Indira Pla^{2,3}, Krzysztof Pawłowski ^{2,4,6}, Carl
- 4 Fehniger^{2,3}, Yvonne Lundberg Giwercman⁵, Irene Leijonhufvud¹, Roger Appelqvist^{2,3}, György
- 5 Marko-Varga^{3,7}, Aniel Sanchez^{2,3†}, and Johan Malm^{2,3†}
- 6 ¹ Molecular Reproductive Medicine, Department of Translational Medicine, Lund University,
- 7 Malmö, Sweden
- 8 ² Section for Clinical Chemistry, Department of Translational Medicine, Lund University, Skåne
- 9 University Hospital Malmö, 214 28 Malmö, Sweden
- ³Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering,
- 11 Lund University, BMC D13, 221 84 Lund, Sweden
- ⁴ Department of Experimental Design and Bioinformatics, Faculty of Agriculture and Biology,
- 13 Warsaw University of Life Sciences SGGW, Warszawa, Poland
- ⁵ Molecular Genetic Reproductive Medicine, Department of Translational Medicine, Lund
- 15 University, Malmö, Sweden
- ⁶ Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas,
- 17 TX, USA
- ⁷ First Department of Surgery, Tokyo Medical University, 6-7-1 Nishishinjiku Shinjiku-ku, Japan
- 19 * [†]The authors share the first and last positions.
- 20 Short title: Novel protein markers of androgen activity
- 21 Key words: testosterone, hypogonadism, proteomics, physiology, biomarker
- 22 Corresponding author and to whom repreint requests should be addressed: Aleksander Giwercman. Dept.
- of Translational Medicine. Lund University. CRC 91-10-058; Jan Waldenströms gata 35; SE 214 28
- 24 Malmö, Sweden. E-mail: aleksander.giwercman@med.lu.se
- 25

It is made available under a CC-BY 4.0 International license .

26 Abstract

Background Reliable biomarkers of vandrogen activity in humans are lacking. The aim of this
study was, therefore, to identify new protein markers of biological androgen activity and test their
predictive value in relation to low vs. normal testosterone values and some androgen deficiency
linked pathologies.

31 Methods Blood samples from 30 healthy GnRH-antagonist treated males were collected at three 32 time points: a) before GnRH antagonist administration; b) 3 weeks later, just before testosterone 33 undecanoate injection, and c) after additional 2 weeks. Subsequently they were analysed by mass 34 spectrometry to identify potential protein biomarkers of testosterone activity. Levels of proteins 35 most significantly associated with testosterone fluctuations were further tested in a cohort of 75 36 hypo- and eugonadal males suffering from infertility. Associations between levels of those 37 markers and cardio-metabolic parameters, bone mineral density as well as androgen receptor CAG 38 repeat lengths, were explored.

Results Using ROC analysis, 4-hydroxyphenylpyruvate dioxygenase (4HPPD), insulin-like growth factor-binding protein 6 (IGFBP6) and fructose-bisphosphate aldolase (ALDOB), as well as a Multi Marker Algorithm, based on levels of 4HPPD and IGFBP6, were shown to be best predictors of low (< 8 nmol/L) vs. normal (> 12 nmol/L) testosterone. They were also more strongly associated with metabolic syndrome and diabetes than testosterone levels. Levels of ALDOB and 4HPPD levels also showed association with AR CAG-repeat lengths.

45 *Conclusions* We identified potential new protein biomarkers of testosterone action. Further
 46 investigations to eluciadate their clinical potential are warranted.

47 Funding: The work was supported by ReproUnion 2.0 (grant no 20201846), which is funded by
48 the Interreg V EU program.

It is made available under a CC-BY 4.0 International license .

49 Introduction

50 The male sex hormone, testosterone (T), plays an important physiological role in regulating 51 function of both reproductive and non-reproductive organs in males as well as in females. In males, 52 the diagnosis of T deficiency (i.e. male hypogonadism) is based on the presence of low serum T 53 levels combined with clinical symptoms, which, however, are not pathognomonic for this 54 condition (1).

The most common way of assessing T activity is by measuring the total concentration of this hormone in a fasting morning blood sample. However, total T does not accurately reflect biological androgenic activity (BAA), which might be considered a more useful biological and clinical marker.

The association between T levels and BAA is affected by several biological mechanisms such as the concentration of binding proteins, body mass index, certain diseases (e.g. diabetes), androgen receptor (AR) sensitivity (2), and different co-factors (3). So far, no reliable algorithms for translating T levels into BAA are available, but could be useful for example in the diagnosis of male hypogonadism.

A correct hypogonadism diagnosis is important for proper identification of men for whom androgen replacement therapy is warranted. However, the treatment of men with hypogonadism represents a clinical challenge, because the symptoms associated with the condition are highly unspecific (4). Furthermore, there are limitations in using the level of T in defining testosterone deficiency. Generally, in many clinical guidelines, total T concentration below 8 nmol/L indicates an insufficient hormone concentration, whereas levels above 12 nmol/L are considered normal (5). Apart from the fact that men with testosterone levels between 8 and 12 nmol/L cannot be assigned

It is made available under a CC-BY 4.0 International license .

to any of these distinct categories, those presenting with a lower or higher hormone concentration may also be misclassified due to an abnormal concentration of sex hormone binding protein (SHBG). Low SHBG levels, as often seen in obese men, may imply low total T despite unaffected BAA. On the other hand, some degree of reduced androgen sensitivity may be associated with decreased BAA despite normal or high testosterone levels (6).

Hypogonadism has been identified as a predictor of several non-communicable chronic diseases as well as premature mortality (7). Understanding the biology of androgen action may therefore contribute to clarifying the pathogenetic mechanisms linking androgen deficiency to comorbid conditions. Thus, the approach based on measuring the protein levels downstream of androgen action is a feasible and logical concept for identifying clinical and biological useful markers of BAA.

Proteomics is a technique aimed to study biological systems based on qualitative and quantitative measuring of proteins and, thereby, integrate the cellular output related to transcription as well as translation. Mapping the quantitative protein response downstream of androgen action may provide new clinically valuable markers of BAA. In order to identify such markers, we compared the protein profile of healthy individuals before and after T deprivation. Subsequently, we assessed the predictive value of the newly identified protein markers in relation to hypogonadism and risk of pathologies related to T deficiency.

89

It is made available under a CC-BY 4.0 International license .

91 Subjects and Methods

92 Study outline

93 The study was set up to I) identify new protein markers of BAA in healthy subjects; II) test the 94 markers' predictive values in relation to biochemically diagnosed hypogonadism, metabolic 95 syndrome (MetS), cardiovascular risk lipid profile (CVRLP), diabetes mellitus II (DM) and low 96 bone density (LBD) in infertile men; III) analyse androgen dependence of the identified proteins 97 by assessing how their levels associate with androgen receptor gene CAG-repeat length.

98 Subjects

All subjects were enrolled with informed written consent. The two studies from which they were
recruited were approved by the Swedish Ethical Review Authority (Approval number: DNR
2014/311, date of approval 8 May 2014; DNR 2011/1, date of approval 11 January 2011).

The first part of the study includes plasma samples obtained from 30 healthy men (biological replicates) aged 19-32 years, BMI 19.1-26.9 kg/m². They, underwent chemical castration by subcutaneous administration of 240 mg GnRH-antagonist (Degeralix®, Ferring Pharmaceuticals, Saint-Prex, Switzerland) followed by remediation of testosterone levels by intramuscular injection of 1000 mg testosterone undecanoate (Nebido®, Bayer AG, Leverkusen, Germany) after the duration of three weeks (8,9). Blood samples were collected at baseline (A); three weeks later (B), and, at the end of the study, after two additional weeks (C) (**Figure 1**).

To test the clinical predictive value of the proteins identified in the castrated men, we used a cohort of 75 serum samples from 75 men (biological replication, subject age 32-43 years) previously recruited for a study on hypogonadism among men from infertile couples (10). Eighty-five patients were randomly selected from 213 infertile men and 223 age-matched controls. The selected

It is made available under a CC-BY 4.0 International license .

patients for the present study had the span of subnormal to upper normal range of T. Out of the 85 patients, ten patients were excluded; seven due to Klinefelter syndrome, one due to missing value of T and the last two were statistical outliers, which were removed after considering the possibles causes. One patient had a high level of T (41.6 nmol/L) without androgen replacement therapy (ART) and the other because he was the only one diagnosed with obstructive azoospermia. Background characteristics of these patients can be found in **Table 1a** and **Table 1b**.



Figure 1. Study design. First, a model of 30 young healthy males was evaluated by proteomics at three time points (A, B and C), where testosterone changes were induced. Identified proteins proposed as candidate biomarkers were then evaluated in a cohort of infertile males. In both steps of the study, the quality of the blood samples was ensured by following an automated workflow for sample aliquoting and storage (-80°C).

It is made available under a CC-BY 4.0 International license .

	Mean (SD)	Ν	
Age at inclusion (years)	37.8 (5.5)	75	
BMI	27.2 (4.3)	72	
Total testosterone (nmol/L)	12.8 (6.8)	75	
FSH (IU/L)	15.8 (14.3)	75	
LH (IU/L)	7.5 (5.7)	75	
Estradiol (pmol/L)	96 (36-321)*	75	
ApoB/ApoA1	0.7 (0.2)	68	
HOMA-IR	1.6 (0.4-13.9)*	75	
DEXA score	-0.5 (1.3)	74	
CAG (repeated length)	22 (14-31)*	74	

Table 1a. Background characteristics of infertile patients.

*Characteristics values are expressed as mean (SD), except for those that did not follow a normal distribution (non-Gaussian) and which are shown as median (min-max) *.*

	n (%)	
Smoker	9 (12.0)	
Current diseases	36 (48.0)	
Insulin medication	1 (1.3)	
Current ART	8 (10.7)	
CVRLP	20 (27.0)	
Insulin resistance	20 (27.0)	
Diabetes Mellitus 2	4 (5.3)	
Metabolic Syndrome (MetS)	14 (20.9)	
Low bone density	23 (30.6)	

Table 1b. Characteristics of the cohort of infertile patients.

Variables are expressed as frequency (n) and percentage of occurrence (%) - according to the total number of patients (N=75). ART: Androgen Replacement Therapy; CVRLP: cardiovascular risk lipid profile

125 The following comorbidities in the cohort of infertile patients were defined MetS, IR, CVRLP,

126 DM and LBD. MetS was determined according to the criteria defined at the National Cholesterol

127 Education Program Adult Treatment Panel III 2002 (Table S1). Homeostatic Model Assessment

128 of Insulin Resistance (HOMA-IR) was calculated as (glucose x insulin)/22.5 and IR was defined

129 as HOMA-IR > 2.5 (11). CVRLP was defined as the ratio apolipoprotein B/apolipoprotein A1 > 120

- 130 0.9 (12). DM was set at fasting blood glucose > 7 mmol/L (13). LBD was determined based on the
- 131 DEXA lumbar Z score with the cut off at < -1 (14). The methods for laboratory tests, CAG-repeat
- 132 length and proteomics are described in the supplementary file 1.

133 Statistical analysis

We briefly describe the statistical analyses performed. A full description of the statistical analysis is available in supplementary file 2. Proteomics data pre-processing was done using Perseus v1.6.7.0 (18) software and unless other software is specified, the statistical analyzes were performed using R software (19,20).

138 Healthy human model

139 Protein intensities were Log2 transformed and standardized by Subtract Median normalization. 140 Differentially expressed proteins were determined by one-way repeated measures ANOVA 141 followed by a pairwise t-test (two-tails and paired). Adjusted p-values < 0.05 were considered 142 significant. The power of the candidate biomarkers to discriminate between normal and low T was 143 evaluated by doing receiver operating characteristic (ROC) analysis. Significant proteins (between 144 A-B with significant recovery in B-C) with a) area under the curve (AUC) > 0.80 or b) AUC 145 between 0.75 - 0.80 and highly enriched in liver tissues (Human Proteome Map (24) and Kampf 146 C. et. al. (25)) were considered candidate biomarker. These candidates were included as predictors 147 in a stepwise regression (method: backward) to select the best combination of markers that predict 148 the odds of being low T. Bootstrap resampling with replacement method was applied to assess 149 consistency. A new variable called Multi Marker Algorithm (MMA) was derived from the 150 predicted log-odds (of being low T) obtained from a binomial logistic regression analysis (see

It is made available under a CC-BY 4.0 International license .

151 supplementary file 2) and it was evaluated together with marker candidates proteins.

152 *Infertile cohort of patients*

The normal distribution of the variables that descrive background characteristics of the infertile cohort of patients (**Table 1a**) was evaluated by Kolmogorov-Smirnov test. The intensities of the candidate biomarkers were Log2 transformed to achieve normal distributions. In this cohort, MMA variable was created to predict the odds of suffering low T or other medical conditions associated with low T levels.

158 Overall changes between more than two groups were evaluated by one-way ANOVA followed by 159 a pairwise FDR correction (29) and adjusted p-values < 0.05 were considered significant. In order 160 to know if the changes in the candidate markers occur with the change in T as observed in the 161 healthy human model, three groups of patients were created based on total T concentration (group 162 1: low T (LT) \leq 8 nmol/L (n= 22); group 2: borderline low T (BL T) between 8 and 12 nmol/L 163 (n=17); group 3: normal T (NT) > 12 nmol/L (n=36)). The power of the candidate biomarkers to 164 discriminate between NT and LT or BL T, or to distinguish patients with medical conditions 165 associated with low T levels (MetS, IR, CVRLP, DM or LBD) was evaluated by a ROC analysis. 166 The DeLong's test (paired) was used to compare the AUCs.

167 To investigate the androgenic dependence of the candidate biomarkers, we looked for associations 168 between their expression and the androgen receptor (AR) CAG repeat length (33-36): reference 169 group 1: patients with CAG repeat length 21 and 22 (n= 18); group 2: patients with CAG repeat

170 length < 21 (n= 26) and group 3: patients with CAG repeat length >22).

171

It is made available under a CC-BY 4.0 International license .

172 **Results**

173 Proteins differentially expressed in chemically castrated men

In total, in the healthy men, the expression level of 31 out of 676 proteins was statistically significantly associated with T concentration (**Tables S2**). The levels of 23 proteins changed in the same direction as T, whereas, the remaining eight markers changed in an opposite way. LH and FSH changed significantly in A-B but not in B-C. The protein changes visualised as boxplots can be found in the Supplementary **Figure S1**.

179 Proteins capable to distinguish between low and normal testosterone

Based on *p*-values for AUC in the ROC analysis, among healthy young men, 90% of the 31 proteins distinguished the low T time point (B) from the normal ones (A and C) with statistical significance (Table S3, **Figure 2a**). ROC-AUC values greater than 0.80 were obtained for the proteins 4-hydroxyphenylpyruvate dioxygenase (4HPPD) and insulin-like growth factor-binding protein 6 (IGFBP6). Additionally, fructose-bisphosphate aldolase (ALDOB) was the only protein enriched in liver tissue with ROC-AUC between 0.75 and 0.80.

The stepwise regression method selected 4HPPD and IGFBP6 as the best markers to be combined to predict the odds of being low T, and thus, they were the basis for the new variable MMA (see Material and Methods). MMA together with 4HPPD, ALDOB and IGFBP6 were selected as potential candidate markers for the diagnosis of BAA (**Figures 2b and 2c**). The expression of the 4HPPD and ALDOB proteins were significantly increased at low T (p<0.001; p<0.001) and remediated in response to the T treatment, whereas IGFBP6 expression was significantly decreased (p<0.001) by castration.

193

It is made available under a CC-BY 4.0 International license .



195 Figure 2. Proteins influenced by testosterone in the model of young healthy males. a) Top 25 196 significant proteins selected in the healthy human model (ROC-p < 0.01, Table S3). The arrows indicate the direction of change in protein expression in the different conditions. The tissue with 197 198 highest expression of each protein is indicated in colours. Also, results from the ROC analysis are 199 shown as bar chart (AUC) and heat-map (p-values). b) Boxplot (mean (min; max)) of the top three 200 significant proteins proposed as biomarker candidates, able to discriminate between low and 201 normal testosterone (Table S4). The adjusted p-values are specified on top of the comparative 202 horizontal lines. c) ROC of the analytes proposed as biomarker candidates, including Multi 203 Marker Algorithm (MMA).

It is made available under a CC-BY 4.0 International license .

204 Testing of the candidate biomarkers in infertile men

205 The three proteins and MMA showed statistically significant differences (4HPPD: p < 0.001, ALDOB: p = 0.003, IGFBP6: p = 0.016, MMA: p < 0.001, Figure 3a) between the three groups 206 207 defined according to the total T levels (Table S2). 4HPPD, ALDOB, and MMA showed a negative 208 association with T changes, while IGFBP6 displayed a positive association. The three proteins and MMA significantly distinguished the patients with LT from BL_T/NT (4HPPD: AUC=0.75, p=209 210 0.001; ALDOB: AUC= 0.70, *p*= 0.008; IGFBP6: AUC= 0.69, *p*= 0.01; MMA: AUC= 0.79, *p*< 211 0.001) (Figure 3b). Additionally, the power to discern low T values improved for all the 212 biomarkers BL T excluded tested when the patients with were (Table 2).



213

Figure 3. New markers to discern states of different testosterone levels in men investigated for infertility (n=75). a) Patients grouped by three levels of total testosterone: low testosterone (LT) $\leq 8 \text{ nmol/L} (n=22)$, border line testosterone (BL_T) between 8 and 12 nmol/L (n=17) and normal testosterone (HT) > 12 nmol/L (n=36). Each group is represented by the mean and its 95% CI.

- 218 Horizontal lines indicate significant differences between groups and the adjusted p-values are
- 219 specified on top of these lines (Table S5). **b**) ROC analysis to discriminate patients with LT in the
- 220 *entire cohort and c) in a cohort that excluded patients with borderline testosterone levels (LT_B).*
- 221 MMA is based on is the combination of levels of the proteins 4HPPD and IGFBP6.

222 Table 2. Comparison of ROC-Areas Under the Curve for testosterone and the candidate biomarkers in relation to the prediction of

223 hypogonadism and its sequels in patients.

	Low	Т	Low	Г*	IR		DM	!	LBI)	CVRI	LP	Met	S
	(T ≤ 8 nr	nol/L)	(T ≤ 8 nr	nol/L)	(HOMA-in	r > 2.5)	-		(z-score	<-1)	(ApoB/Apo/	4 <i>1 ≥ 0.9)</i>		
Analyte	AUC (Sp,Se)	p	AUC (Sp,Se)	p	AUC (Sp,Se)	р	AUC (Sp,Se)	p	AUC (Sp,Se)	р	AUC (Sp,Se)	р	AUC (Sp,Se)	р
4HPPD	0.75 (85,59)	<u>8.38E-04</u>	0.77 (86,59)	<u>2.66E-04</u>	0.79 (84,70)	<u>1.20E-04</u>	0.89 (93,75)	<u>9.00E-03</u>	0.64 (76,61)	<u>2.24E-02</u>	0.74 (46,90)	<u>5.79E-03</u>	0.74 (95,50)	<u>5.31E-03</u>
ALDOB	0.69 (68,73)	<u>8.25E-03</u>	0.70 (67,73)	<u>5.39E-03</u>	0.73 (71,75)	<u>2.85E-03</u>	0.85 (63,100)	<u>1.80E-02</u>	0.57 (98,27)	1.93E-01	0.71 (83,55)	<u>4.64E-02</u>	0.74 (82,64)	<u>6.02E-03</u>
IGFBP6	0.69 (77,59)	<u>1.05E-02</u>	0.70 (81,59)	<u>4.89E-03</u>	0.57 (42,80)	3.50E-01	0.59 (39,100)	5.40E-01	0.63 (43,78)	2.75E-01	0.59 (48,80)	1.87E-01	0.65 (45,93)	8.45E-02
Testosterone	-	-	-	-	0.71 (76,70)	<u>4.96E-03</u>	0.55 (32,100)	7.24E-01	0.75 (74,74)	<u>5.12E-04</u>	0.66 (65,85)	<u>6.55E-03</u>	0.56 (72,57)	5.08E-01
MMA	0.79 (74,82)	<u>9.23E-05</u>	0.80 (72,86)	<u>3.86E-05</u>	0.79 (82,70)	<u>1.46E-04</u>	0.92 (84,100)	<u>5.00E-03</u>	0.78 (82,65)	<u>1.40E-02</u>	0.75 (73,75)	<u>3.65E-03</u>	0.78 (63,86)	<u>1.57E-03</u>

Significant p-values are highlighted in bold and underlined. * Excluding patients with testosterone values from the borderline low testosterone ($8 < BL_T \le 12$).

IR: insulin resistance; DM: diabetes mellitus type 2; LBD: low bone density; CVRLP: cardiovascular risk lipid profile ; MetS: metabolic syndrome

AUC: area under the curve; Spe: Specificity in %; Se: Sensitivity in %

It is made available under a CC-BY 4.0 International license .

Ability to distinguish men with abnormal metabolic comorbidities or reduced bone mineral density

227	The AUCs for 4HPPD, ALDOB and MMA in relation to risk of DM and MetS were statistically
228	significant whereas for T the p-value for AUC was 0.72. The AUCs for 4HPPD, ALDOB and
229	MMA were also statistically significantly larger than this for T (DM: 4HPPD (p = 0.005), ALDOB
230	(p=0.009), MMA $(p=0.002)$; MetS: 4HPPD $(p=0.032)$, ALDOB $(p=0.030)$, MMA $(p=0.002)$),
231	(Table 2). Additionally, the AUC values in relation to CVRLP and IR were numerically higher
232	for 4HPPD, ALDOB and MMA than for T, however, the differences between the AUC values
233	were not statically significant (CVRLP marker vs T: 4HPPD $(p=0.97)$, ALDOB $(p=0.61)$, MMA
234	(p=0.87); IR marker vs T: 4HPPD vs T $(p=0.30)$, ALDOB vs T $(p=0.88)$, MMA $(p=0.31)$).
235	4HPPD and MMA statistically significantly distinguished between patients with normal bone
236	density and LBD. The same was true for T, the differences between the AUC for T and those for
237	4HPPD and MMA not being statistically significant (LBD vs T: 4HPPD ($p=0.28$), MMA ($p=$
238	0.30)). No statistical significance, in relation to prediction of LBD was found for IGFBP6 (Figure
239	4)

It is made available under a CC-BY 4.0 International license .



240

Figure 4 Results from ROC analysis to determine whether the analytes discriminate between the
presence of comorbidities or not. Analytes included in the analysis are 4HPPD, IGFBP6, ALDOB
and MMA (combination of 4HPPD and IGFBP6). AUC, p-values can be found in Table 2. IR:
insulin resistance; DM: type 2 diabetes mellitus; LBD: low bone density; CVRLP: cardiovascular
risk lipid profile; MetS: metabolic syndrome.

246

247 Association of the candidate biomarkers with androgen receptor CAG-repeat length

248 Statistically significant inter-CAG-group overall differences were observed for 4HPPD (p=0.012)

and ALDOB (p=0.008) (Figure 5). Additionally, the protein expressions were significantly higher

- in the groups with <21 and >22 CAG repeat length as compared with the reference (Table 3 and
- **Figure 5**). However, we did not observe any statistically significant association between CAG

It is made available under a CC-BY 4.0 International license .

252 number and expression of IGFBP6.

253 Table 3. Ratio between mean concentrations of 4HPPD and ALDOB in men with CAG repeat

length < 21 or >22 as compared to the reference group

Ductoing	Overall	<21 vs refere	nce	>22 vs reference		
Froteins	p-value	ratio (95% CI)	p value*	ratio (95% CI)	p value*	
4HPPD	0.012	1.34 (1.02 to 1.76)	0.032	1.62 (1.23 to 2.13)	0.001	
ALDOB	0.008	1.35 (1.03 to 1.78)	0.029	1.72 (1.29 to 2.32)	< 0.001	

Ratio: ratio between mean concentration in <21 or >22 groups divided by the reference group (21 and 22).

* *p*-value of the post hoc constrain between groups



Figure 5. Association between androgen receptor CAG <21 (n=26), and CAG<22 (n=30) and 4HPPD and ALDOB, respectively, with CAG=21 and 22 (n=18) set as reference.

It is made available under a CC-BY 4.0 International license .

256 Discussion

257 We have identified three plasma proteins, which are potential markers of BAA. In young healthy 258 men the three markers ALDOB, 4HPPD and IGFB6 were strongly associated with T levels. In a 259 slightly older cohort of infertile men, these markers were indicative of T deficiency (5). 260 Furthermore, levels of two of the markers, ALDOB and 4HPPD, were more strongly associated 261 with risk of metabolic disturbances than total T. The association seemed to become stronger by 262 creating a combined marker MMA, based on both 4HPPD and IGFBP6 levels. Finally, the 263 androgen dependence of ALDOB and 4HPPD was confirmed by the association between the 264 concentration of those proteins and the length of androgen receptor CAG repeats.

265 The ALDOB is a glycolytic enzyme, predominantly expressed in liver and kidney, that catalyzes 266 the reversible cleavage of fructose-1,6-bisphosphate into glyceraldehyde 3-phosphate and 267 dihydroxyacetone phosphate. The B isoform of aldolase, e.g. ALDOB, in the liver is under dietary 268 control (37). Ingestion of fructose induces ALDOB mRNA expression in the liver, which is 269 otherwise low in fasting conditions. In humans, absence of functional ALDOB enzyme due to 270 mutations in the ALDOB gene cause hereditary fructose intolerance, characterized by metabolic 271 disturbances that include hypoglycemia, lactic acidosis, and hypophosphatemia (38). An upregulation of ALDOB in human pancreatic β -cells occurs upon the development of 272 273 hyperglycemia and may contribute to the impairment of insulin secretion in humans (39). In a 274 study on goats, the ALDOB gene was found to be downregulated at the time of post-natal initiation 275 of spermatogenesis (40). This finding is in accordance with our data showing that rising 276 testosterone is inhibiting ALDOB.

277 Similar to ALDOB, we found that 4HPPD was negatively associated with T levels. This enzyme

278 is involved in the catabolic pathway of tyrosine and catalyzes the conversion of 4-279 hydroxyphenylpyruvate to homogentisic acid in the tyrosine catabolism pathway (41). The 280 expression of the gene is regulated by hepatocyte-specific and liver-enriched transcription factors, 281 as well as by hormones (24). Tyrosine has previously been reported to be upregulated in 282 hypogonadal men and both tyrosine and phenylalanine levels were suggested as predictors of the 283 risk of developing diabetes many years before manifest disease (43-45). In male tyrosine 284 hydroxylase knock-out mice normal body weight, puberty onset, and basal gonadotropin levels in 285 adulthood were evident, although T was significantly elevated in adult mice (46).

286 The last marker, IGFBP6 is expressed in most tissues (24) and is one of the binding proteins for 287 Insulin-Like Growth Factor (IGF). The principal function of IGFBP-6 is inhibiting IGF-II actions, whereby IGF-II induced cell proliferation, differentiation, migration and survival is reduced. 288 289 Serum levels of IGFBP-6 increase gradually with age and are higher in men than in women, but 290 there are conflicting studies of the direct effects of sex steroids on IGFBP-6 expression in different 291 tissues (47). A positive association between the levels of T and IGFBP-6 have previously been 292 found (48) (49). The latter study has a somewhat similar set up as the present study, based on 293 chemical castration with a GnRH agonist, and has also focused on identifying novel markers of 294 BAA, but with candidate markers previously identified as being associated with changes in fat-295 free mass. The study showed that early increases in IGFBP6 levels in men receiving testosterone 296 were associated with increases in fat-free mass and muscle strength.

Altogether, our findings may not only be clinically valuable in developing new methods of assessing BAA but also add to our understanding of the biological role of T in human metabolism, regulation of testicular function (ALDOB), as well as muscle strength and body composition

It is made available under a CC-BY 4.0 International license .

(IGFBP6). The combined parameter MMA may in this context be an important tool in the detection
 of long-term morbidity, such as bone mineral density and cardio-metabolic risk, even before
 clinical diagnosis.

303 Our study has some strengths and limitations. Using a chemical castration model in young healthy 304 men, we were able to identify proteins influenced by androgens and select those that were most 305 strongly associated with T levels. By utilizing proteomics, we had an explorative approach to 306 identify new markers of BAA without being restricted by previously published findings.

Another strength is the depth of the analysis due to the depletion abundant proteins from plasma. We were able to identify more than 450 proteins, which were identified in the same concentration range as 87 % of FDA-approved biomarkers (50). If depletion is not performed the detection level is dampened by the components from the digested abundant proteins as the proteins removed are of highest abundance in plasma and plasma proteome and exceed some lower abundance proteins by 10 orders of magnitude (51).

Although more clinical testing is needed, we have provided preliminary results showing that these protein markers may also be clinically useful. We have previously shown that median length CAG number is associated with most active AR (52). Thus, the fact that we find the lowest ALDOB and 4HPPD levels in those subjects having AR CAG repeat length close to median, confirms that the candidate markers identified in the present study are androgen dependent.

A limitation of our study is that the lack of reliable criteria for clinical hypogonadism, which made it impossible to test the power of the new markers in men in whom androgen replacement is needed. Furthermore, the clinical part of the study was limited, because we do not have sufficient

It is made available under a CC-BY 4.0 International license .

information about potential factors influencing the inter- and intra-individual variation in the levelsof these proteins and, thereby, their suitability as clinical markers.

323 Furthermore, we are not reporting absolute values of quantifications for the potential markers, but 324 the relative quantifications for comparing the protein expression between groups. This kind of 325 comparative proteomics is favorable in research studies, in which preliminary results of protein 326 changes between groups are obtained. Also, the sample processing is complicated putting high 327 demands on the lab. In proteomics, there can be a high variation between labs in reporting absolute 328 concentration proteins in plasma, especially when small sample sizes are reported (53). In order to 329 obtain trustworthy absolute concentration ranges or determine the activity level of the enzymes, it 330 is necessary to analyze the potential markers in large cohorts including both healthy subjects and 331 patients.

In this study, we have applied an immunoassay for measuring T levels, although some consider liquid chromatography-tandem mass spectrometry (LC-MS/MS) as gold standard in assessment of sex hormone levels. However, worldwide the former is most commonly used for T measurements. Additionally, in prediction of cardiometabolic risk, assessment of T by LC-MS/MS was not shown to be superior to that performed by standard methodology (54).

In conclusion, we have identified three new potential biomarkers of BAA. Those proteins – alone or in combination – are promising as useful parameters in the clinical diagnosis of male hypogonadism and in the prediction of its long-term sequelae, as well as in studying the biology of androgen action. More extensive testing is vital to elucidate their BAA potential, not only in men but also in women and in prepubertal boys.

It is made available under a CC-BY 4.0 International license .

342 Data availability

- 343 The mass spectrometry proteomics data have been deposited to the ProteomeX change Consortium
- 344 via the PRIDE (55) partner repository with the dataset identifier PXD024448.
- 345 Supplementary tables (datasets):
- 346 https://doi.org/10.6084/m9.figshare.14875431
- 347 Source data of the Figures can be found on:
- 348 https://doi.org/10.6084/m9.figshare.14875431
- 349 Supplementary Figure S1:
- 350 https://doi.org/10.6084/m9.figshare.14876562
- 351 R code:
- 352 <u>https://github.com/indirapla/TP1_proteins_marker_of_androgen_activity</u>
- 353
- 354 **Declaration of conflict of interest**: The authors declare that there is no conflict of interest that
- 355 could be perceived as prejudicing the impartiality of the research reported.
- 356

It is made available under a CC-BY 4.0 International license .

358 References

- Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone deficiency. Am J Med.
 2011;124(7):578–87.
- Zitzmann M. The Role of the CAG Repeat Androgen Receptor Polymorphism in
 Andrology. In: Advances in the Management of Testosterone Deficiency. Basel: KARGER;
 2008. p. 52–61.
- Furuya K, Yamamoto N, Ohyabu Y, Morikyu T, Ishige H, Albers M, et al. Mechanism of
 the tissue-specific action of the selective androgen receptor modulator s-101479. Biol
 Pharm Bull. 2013 Mar;36(3):442–51.
- Miner M, Barkin J, Rosenberg MT. Testosterone deficiency: myth, facts, and controversy.
 Can J Urol. 2014 Jun;21 Suppl 2(3):39–54.
- 369 5. Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. Vol.
 370 37, Frontiers of Hormone Research. Front Horm Res; 2009. p. 5–20.
- Diaz-Arjonilla M, Schwarcz M, Swerdloff RS, Wang C. Obesity, low testosterone levels
 and erectile dysfunction. Vol. 21, International Journal of Impotence Research. Int J Impot
 Res; 2009. p. 89–98.
- 374 7. Muraleedharan V, Jones TH. Testosterone and mortality. Clin Endocrinol (Oxf).
 375 2014;81(4):477–87.
- 3768.Sahlin KB, Pla I, Sanchez A, Pawłowski K, Leijonhufvud I, Appelqvist R, et al. Short-term

- effect of pharmacologically induced alterations in testosterone levels on common blood
 biomarkers in a controlled healthy human model. Scand J Clin Lab Invest. 2019 Nov
 18;80(1):1–7.
- 9. Pla I, Sahlin KB, Pawłowski K, Appelqvist R, Marko-Varga G, Sanchez A, et al. A pilot
 proteomic study reveals different protein profiles related to testosterone and gonadotropin
 changes in a short-term controlled healthy human cohort. J Proteomics. 2020 May
 30;220:1–3.
- Bobjer J, Bogefors K, Isaksson S, Leijonhufvud I, Åkesson K, Giwercman YL, et al. High
 prevalence of hypogonadism and associated impaired metabolic and bone mineral status in
 subfertile men. Clin Endocrinol (Oxf). 2016 Aug;85(2):189–95.
- Wickramasinghe VP, Arambepola C, Bandara P, Abeysekera M, Kuruppu S, Dilshan P, et
 al. Insulin resistance in a cohort of 5-15 year old children in urban Sri Lanka. BMC Res
 Notes. 2017 Jul;10(1).
- Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: Risk indicators of
 coronary heart disease and targets for lipid-modifying therapy. Vol. 255, Journal of Internal
 Medicine. 2004. p. 188–205.
- 393 13. Standards of Medical Care in Diabetes-2010. 2010;
- Isaksson S, Bogefors K, Åkesson K, Egund L, Bobjer J, Leijonhufvud I, et al. Risk of low
 bone mineral density in testicular germ cell cancer survivors: association with
 hypogonadism and treatment modality. Andrology. 2017;5(5):898–904.

- Lundin KB, Giwercman A, Richthoff J, Abrahamsson PA, Giwercman YL. No association
 between mutations in the human androgen receptor GGN repeat and inter-sex conditions.
 Mol Hum Reprod. 2003;9(7–8):375–9.
- 400 16. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al.
- 401 Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76–85.
- 402 17. MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline:
 403 an open source document editor for creating and analyzing targeted proteomics
 404 experiments. Bioinformatics. 2010 Apr 1;26(7):966–8.
- 405 18. Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus
 406 computational platform for comprehensive analysis of (prote)omics data. Nat Methods.
 407 2016 Sep 27;13(9):731–40.
- 408 19. RStudio Team. RStudio: Integrated Development for R. RStudio. Boston; 2016.
- 409 20. Team RC. R: A language and environment for statistical computing. R Foundation for
 410 Statistical Computing. 2016.
- 411 21. Marshall KW, Mohr S, Khettabi F El, Nossova N, Chao S, Bao W, et al. A blood-based
 412 biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2009
 413 Mar;126(5):1177–86.
- 414 22. Bowers AJ, Zhou X. Receiver Operating Characteristic (ROC) Area Under the Curve
 415 (AUC): A Diagnostic Measure for Evaluating the Accuracy of Predictors of Education

- 416 Outcomes. J Educ Students Placed Risk. 2019 Jan;24(1):20–46.
- 417 23. Šimundić A-MM. Measures of Diagnostic Accuracy: Basic Definitions. Ejifcc. 2009
 418 Jan;19(4):203–11.
- 419 24. Kim M-SS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Chaerkady R, et al. A draft map
 420 of the human proteome. Nature. 2014 May 29;509(7502):575–81.
- 421 25. Kampf C, Mardinoglu A, Fagerberg L, Hallström BM, Edlund K, Lundberg E, et al. The
 422 human liver-specific proteome defined by transcriptomics and antibody-based profiling.
- 423 FASEB J Res Commun.
- 424 26. Kholodenko I V, Yarygin KN. Cellular Mechanisms of Liver Regeneration and Cell-Based
 425 Therapies of Liver Diseases. Biomed Res Int. 2017;v.2017:17 pages.
- 426 27. Schmucker DL, Sanchez H. Liver Regeneration and Aging: A Current Perspective. Curr
 427 Gerontol Geriatr Res. 2011;2011.
- 428 28. Youden WJ. Index for rating diagnostic tests. Cancer. 1950 Jan;3(1):32–5.
- 429 29. Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the
 430 false discovery rate. Biometrika. 2006 Sep 1;93(3):491–507.
- 431 30. Chan I, Tang Fui MN, Zajac JD, Grossmann M. Assessment and management of male
 432 androgen disorders: An update. Aust Fam Physician. 2014;43(5):277–82.
- 433 31. Lunenfeld B, Arver S, Moncada I, Rees DA, Schulte HM. How to help the aging male?

434	Current approaches to hypogonadism in primary care. Vol. 15, Aging Male. Aging Male;
435	2012. p. 187–97.

- 436 32. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks
 437 with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91(11):4335–43.
- 438 33. Casella R, Maduro MR, Lipshultz LI, Lamb DJ. Significance of the polyglutamine tract
 439 polymorphism in the androgen receptor. Urology. 2001;58(5):651–6.
- 440 34. Stanworth RD, Kapoor D, Channer KS, Jones TH. Androgen receptor CAG repeat
 441 polymorphism is associated with serum testosterone levels, obesity and serum leptin in men
 442 with type 2 diabetes. Eur J Endocrinol. 2008;159(6):739–46.
- Kim JW, Bae YD, Ahn ST, Kim JW, Kim JJ, Moon DG. Androgen Receptor CAG Repeat
 Length as a Risk Factor of Late-Onset Hypogonadism in a Korean Male Population. Sex
 Med. 2018 Sep 1;6(3):203–9.
- 446 36. Ferlin A, Bartoloni L, Rizzo G, Roverato A, Garolla A, Foresta C. Androgen receptor gene
 447 CAG and GGC repeat lengths in idiopathic male infertility. Mol Hum Reprod.
 448 2004;10(6):417–21.
- 449 37. Munnich A, Besmond C, Darquy S, Reach G, Vaulont S, Dreyfus JC, et al. Dietary and
 450 hormonal regulation of aldolase B gene expression. J Clin Invest. 1985;75(3):1045–52.
- 451 38. Hannou SA, Haslam DE, McKeown NM, Herman MA. Fructose metabolism and metabolic
 452 disease. Vol. 128, Journal of Clinical Investigation. American Society for Clinical

- 453 Investigation; 2018. p. 545–55.
- Gerst F, Jaghutriz BA, Staiger H, Schulte AM, Lorza-Gil E, Kaiser G, et al. The expression
 of aldolase B in islets is negatively associated with insulin secretion in humans. J Clin
 Endocrinol Metab. 2018;103(12):4373–83.
- 457 40. Bo D, Jiang X, Liu G, Xu F, Hu R, Wassie T, et al. Multipathway synergy promotes
 458 testicular transition from growth to spermatogenesis in early-puberty goats. BMC
 459 Genomics. 2020 May 25;21(1).
- 460 41. Hager SE, Gregerman RI, Kox WE. p-Hydroxyphenylpyruvate oxidase of liver. J Biol
 461 Chem. 1957;225(2):935–47.
- 462 42. Barroso F, Correia J, Bandeira A, Carmona C, Vilarinho L, Almeida M, et al. Tyrosinemia
 463 type III: A case report of siblings and literature review. Revista Paulista de Pediatria. 2020.
- 464 43. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles
 465 and the risk of developing diabetes. Nat Med. 2011 Apr;17(4):448–53.
- 466 44. Fanelli G, Gevi F, Belardo A, Zolla L. Metabolic patterns in insulin-sensitive male
 467 hypogonadism article /101/58. Cell Death Dis. 2018 Jun 1;9(6).
- 468 45. Guasch-Ferré M, Hruby A, Toledo E, Clish CB, Martínez-González MA, Salas-Salvadó J,
 469 et al. Metabolomics in prediabetes and diabetes: A systematic review and meta-analysis.
 470 Diabetes Care. 2016.
- 471 46. Stephens SBZ, Rouse ML, Tolson KP, Liaw RB, Parra RA, Chahal N, et al. Effects of

- 472 selective deletion of tyrosine hydroxylase from kisspeptin cells on puberty and reproduction
 473 in male and female mice. eNeuro. 2017;
- 474 47. Bach LA, Fu P, Yang Z. Insulin-like growth factor-binding protein-6 and cancer. Clinical
 475 Science. 2013.
- 476 48. Rooman RPA, Op De Beeck L, Martin M, van Doorn J, Mohan S, Du Caju MVL.
 477 Ethinylestradiol and testosterone have divergent effects on circulating IGF system
 478 components in adolescents with constitutional tall stature. Eur J Endocrinol. 2005
 479 Apr;152(4):597–604.
- 480 49. Huang G, Rocha G V., Pencina KM, Cox K, Krishnan V, Henriksen K, et al. Circulating
 481 Biomarkers of Testosterone's Anabolic Effects on Fat-Free Mass. J Clin Endocrinol Metab.
 482 2019 Apr 11;104(9):3768–78.
- 483 50. Anderson NL. The Clinical Plasma Proteome: A Survey of Clinical Assays for Proteins in
 484 Plasma and Serum. Clin Chem. 2010 Feb;56(2):177–85.
- 485 51. Tu C, Rudnick PA, Martinez MY, Cheek KL, Stein SE, Slebos RJC, et al. Depletion of
 486 abundant plasma proteins and limitations of plasma proteomics. J Proteome Res. 2010
 487 Oct;9(10):4982–91.
- 488 52. Nenonen H, Björk C, Skjaerpe PA, Giwercman A, Rylander L, Svartberg J, et al. CAG
 489 repeat number is not inversely associated with androgen receptor activity in vitro. Mol Hum
 490 Reprod. 2009 Nov;16(3):153–7.

It is made available under a CC-BY 4.0 International license .

491 55. Nanjappa V, Thomas JK, Marimulnu A, Mulhusamy B, Kaunakrishnan A, Si
--

- 492 Plasma Proteome Database as a resource for proteomics research: 2014 update. Nucleic
 493 Acids Res. 2014 Jan;42(D1):D959–65.
- 494 54. Haring R, Baumeister SE, Nauck M, Volzke H, Keevil BG, Brabant G, et al. Testosterone
- 495 and cardiometabolic risk in the general population the impact of measurement method on
- 496 risk associations: A comparative study between immunoassay and mass spectrometry. Eur
- 497 J Endocrinol. 2013 Oct;169(4):463–70.
- 498 55. Perez-Riverol Y, Csordas A, Bai J, Bernal-Llinares M, Hewapathirana S, Kundu DJ, et al.
- 499 The PRIDE database and related tools and resources in 2019: improving support for 500 quantification data. Nucleic Acids Res. 2019 Jan 8;47(D1):D442–50.

It is made available under a CC-BY 4.0 International license .

502 SUPPLEMENTARY MATERIAL

503 Supplementary method description

504 *Laboratory tests and dual X-ray absorptiometry*

505 The analysis of the clinical chemistry parameters as well as bone mineral density were conducted 506 as previously described (1) in the study on infertile men. Markers measured in fasting morning 507 plasma samples included: total T, luteinizing hormone (LH), follicle stimulating hormone (FSH), 508 estradiol (E2), glucose, insulin, apolipoprotein A1, and apolipoprotein B. The parameters were 509 analyzed at the Department of clinical chemistry, Skåne University Hospital, Malmö, Sweden. 510 Total testosterone, LH and FSH were measured by electrochemiluminescence immunoassay 511 (ECLIA) and an immunofluorometric method (DELFIA Estradiol, Wallac OY, Finland) was 512 utilized to measure E2. Glucose was measured by an automated hexokinase method and insulin 513 was measured by immunometric sandwich assay. Bone mineral density (BMD, g/cm²) at total hip 514 (TH) and lumbar spine L1–L4 (LS) was measured using dual X-ray absorptiometry.

515 <u>CAG-repeat length</u>

Androgen receptor CAG-repeat length was determined in all the infertile men. For the analysis,
DNA was extracted from peripheral leukocytes. The androgen receptor CAG stretch was amplified
by polymerase chain reaction (PCR), purified and directly sequenced in a Beckman Coulter CEQ
2000 XL (Beckman Coulter, Bromma, Sweden) as previously described (2).

520 <u>Proteomics experiments</u>

521 All chemical reagents for the proteomic analysis not specified in the text were purchased from

It is made available under a CC-BY 4.0 International license .

522 Sigma Aldrich (St. Louis, MO). Modified porcine trypsin was from Promega (Madison, WI), water

523 from Milli-Q Ultrapure Water system (Millipore, Billerica, MA). Water and organic solvents for

524 LC-MS were of LC-MS quality (Merck, Darmstadt, Germany).

525 The plasma and serum samples from respective cohort (healthy men and infertile patients) were 526 randomized regarding the order before starting sample preparation. Quantitation of total protein 527 content in the samples was performed using the bicinchoninic acid (BCA) assay (3). Following 528 the instructions provided by the manufacturer, the top seven most-abundant proteins (albumin, 529 IgG, IgA, transferrin, haptoglobin, antitrypsin and fibrinogen) were depleted from approximately 530 10 µL of each sample using a MARS7 column (Agilent, Santa Clara, CA). The buffer was 531 exchanged to 1.6% SDC, 50 mM NH₄HCO₃ with Amicon ultra-centrifugal filters (0.5 mL, 10 kDa 532 cut-off, Millipore, Tullagreen, Ireland). The disulphide bonds were reduced by adding DTT to a 533 final concentration of 10 mM and incubated 1 h at 37 °C. The free thiol groups were alkylated by 534 adding iodoacetamide to a final concentration of 25 mM, and the reaction proceeded for an 535 additional 30 min at room temperature in darkness (reduction and alkylation occurred in the 536 Amicon filter). The buffer was exchanged to 50 mM NH₄HCO₃ and the samples were resuspended 537 in 100 µL 50mM NH₄HCO₃ (30 µg protein after BCA quantitation) and digested with trypsin at 538 an enzyme-to-substrate mass ratio of 1:30 (w/w) for 16 h at 37°C. The remaining SDC was 539 precipitated by adding 20% formic acid prior to filtering the samples through a polypropylene filter 540 plate with a hydrophilic PVDF membrane (mean pore size 0.45 µm, Porvair Filtration Group, 541 Fareham, UK).

A Q-Exactive Plus mass spectrometer connected to an Easy-nLC 1000 liquid chromatography
system (Thermo Scientific, San José, CA, USA) was used to analyse the samples for automated

544 Data Dependent Acquisition (DDA) methods. Peptides (2 μ L, 1 μ g on the column) were loaded 545 onto an Acclaim PepMap 100 precolumn (75 μ m × 2 cm, Thermo Scientific, San José, CA, USA) 546 and separated on an easy-Spray column (25 cm × 75 μ m i.d., PepMap C18 2 μ m, 100 Å) at a flow 547 rate of 300 nL/min and a column temperature of 35°C. Solvent A (0.1% formic acid) and solvent 548 B (0.1% formic acid in acetonitrile) were used to create a nonlinear gradient to elute the peptides 549 (90 min).

550 The MS1 spectra of the peptides were acquired in the orbitrap mass analyser from m/z 400–1600 551 and a resolution of 70,000 (at m/z 200). The target automated gain control (AGC) value and 552 maximum injection time (IT) were 1e6 and 100 ms, respectively. The ten most intense peaks with 553 charge state ≥ 2 were fragmented by higher-energy collisional dissociation (HCD) with 26% 554 normalised collision energy. Tandem mass spectra were acquired in the orbitrap mass analyser at 555 a resolution of 35,000 (at m/z 200), a target AGC value of 5e4 and a maximum IT of 100 ms. The 556 underfill ratio was 10% and dynamic exclusion was 45 s. The normalised collision energy was 557 26%.

Selected proteins from the heatly individuals were monitored also in patients by Multiple 558 559 Reaction Monitoring (MRM) method. A TSQ Quantiva mass spectrometer equipped with an 560 EASY-Spray NG ion source and connected to an EASY n-LC 1000 liquid chromatography system 561 (Thermo Scientific, San José, CA, USA) was used for the MRM method. Peptides (5 µL, 1 µg on 562 the column) were loaded onto an Acclaim PepMap 100 precolumn (100 μ m \times 2 cm, Thermo 563 Scientific, San José, CA, USA) and separated on an easy-Spray column (15 cm \times 75 μ m i.d., 564 PepMap C18 3 µm, 100 Å) at a flow rate of 300 nL/min and a column temperature of 35°C. Solvent 565 A (0.1% formic acid) and solvent B (0.1% formic acid in acetonitrile) were used to create a

nonlinear gradient to elute the peptides (60 min). Internal references, isotopically labelled synthetic 566 567 peptides (UVic-Genome BC Proteomics Centre, BC, Canada) were added in order to determine 568 relative quantifications of proteins. Data was acquired in scheduled MRM mode with 5 min 569 detection windows. SRM transitions were acquired in O1 and O3 operated at unit resolution (0.7 570 full with at half maximun, FWHM), the collision gas pressure in O2 was 1.5 mTorr. The cycle 571 time was 2 s, and calibrated radio frequency (RF) and S-lens values were used. At least three 572 transition per precursor were monitored and in most cases the ratio is reported between the relative 573 total intensities vs the references.

574 For peptide and protein identification the Proteome Discoverer v2.2 (PD) software (Thermo 575 Scientific, San José, CA) was used. Peptides were identified using SEQUEST HT against UniProt 576 (http://www.uniprot.org) human database (Human 9606, Reviewed, 20 165) integrated into PD. 577 The search was performed with the following parameters: cysteine carbamidomethylation as a 578 static modification, oxidation of methionine as a dynamic modification, 10 ppm precursor 579 tolerance and 0.02 Da fragment tolerance. Up to one missed cleavage for tryptic peptides was 580 allowed. According to the PD software, the filters applied were high- (FDR<0.01) and medium 581 confidence (FDR<0.05) at peptide- and protein levels, respectively. The peptide and protein 582 quantifications were based on the quantification of MS peptide signals (label-free quantification). 583 Label-free quantification used the Minora Feature Detector node in the processing workflow, and 584 the Precursor Ions Quantifier node and the Feature Mapper in the consensus workflow.

585 To analyse the MRM data, all MS files were imported into Skyline v3.5(4) (MacCoss Lab 586 Software, Seattle, WA). The peak integration was performed automatically by the software, using 587 Savitzky-Golay smoothing and to confirm the correct peak detection it was in addition, manually

It is made available under a CC-BY 4.0 International license .

inspected. The relative total intensities vs the references (ratios), were reported as expression values. Only the values that passed the inspected intensity selection criteria according to PD or in Skyline were reported.

591 <u>References (Supplementary methods)</u>

592

- Bobjer J, Bogefors K, Isaksson S, Leijonhufvud I, Åkesson K, Giwercman YL, et al. High
 prevalence of hypogonadism and associated impaired metabolic and bone mineral status in
 subfertile men. Clin Endocrinol (Oxf) [Internet]. 2016 Aug [cited 2018 Nov 26];85(2):189–
 95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26857217
- Lundin KB, Giwercman A, Richthoff J, Abrahamsson PA, Giwercman YL. No association
 between mutations in the human androgen receptor GGN repeat and inter-sex conditions.
 Mol Hum Reprod [Internet]. 2003 [cited 2021 Jan 14];9(7–8):375–9. Available from:
 https://pubmed.ncbi.nlm.nih.gov/12802043/
- Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al.
 Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150(1):76–85.
- MacLean B, Tomazela DM, Shulman N, Chambers M, Finney GL, Frewen B, et al. Skyline:
 an open source document editor for creating and analyzing targeted proteomics
 experiments. Bioinformatics. 2010 Apr;26(7):966–8.

It is made available under a CC-BY 4.0 International license .

608 Supplementary Statistical analyses

609 *Identification of candidate marker proteins from chemically castrated men*

610 Proteins identified by mass spectrometry techniques in samples from healthy subjects were pre-611 processed in Perseus v1.6.7.0 (1) software. Intensities were Log2 transformed to follow a normal 612 distribution and standardized by subtracting the median of its respective sample from each value. 613 The statistical analyses were performed using R software (2,3) and SPSS Statistics 21.0 (IBM, 614 Somers, IL, USA). Differentially expressed proteins were determined by doing one-way repeated 615 measures ANOVA (R function: ezANOVA{ez}) to reveal overall differences between conditions 616 (normal (A), low (B) and restored (C) T) and differences between individual conditions were 617 detected by performing a post-hoc test based on pairwise t-test (two-tails and paired) (R function: 618 pairwise.t.test{stats}). The 'pairwise.t.test' function utilized the proteins with significant overall 619 changes (ANOVA p-value < 0.05) to perform pairwise comparisons between conditions while 620 corrected for multiple pairwise testing. Proteins with adjusted p-values ('fdr' method) < 0.05621 following the pairwise t-test were considered significant.

Because gonadotropins (FSH, LH) did not change their levels between conditions B and C, while T did recover its value (4), proteins that changed with statistical significance between A-B and recovered their values significantly between B and C were considered mainly influenced by T changes and, hence, were selected for further analyses.

Based on the outcome of the first selection step of the analysis, we performed receiver operating
characteristic (ROC) analysis to select proteins capable to discriminate between normal and low
T. Two categories of samples were created: 'low T' that included samples evaluated at time point

629 B and 'normal T' that included samples evaluated at time point A and C. Although there is no 630 consensus about the threshold for sufficient diagnostic accuracy, the area under the curve (AUC) 631 can be interpreted as the following rough classifying system: > 0.90 = excellent; 0.80 - 0.90 = very 632 good; > 0.70 - 0.80 = good; 0.60 - 0.70 = sufficient and 0.50 - 0.60 = poor (5-7). Consequently, 633 based on the ROC-AUC values, we created two cut-off values to select the final protein 634 biomarkers: a) AUC > 0.80 (i.e. very good) and b) AUC 0.75 - 0.80 (i.e. good) and highly enriched 635 in liver tissues (according to the Human Proteome Map (8) and Kampf C. et. al. (9)), which, unlike 636 other organs, appears to be relatively protected from age-related changes (10,11). The Human 637 Proteome Map tool (8) was used to determine the tissue-specific localization of the proteins.

638 Because the combination of different markers may improve the discriminative power to diagnose 639 hypogonadism and predict its long term sequelae, proteins selected from the ROC-AUC analysis 640 were included as predictors in a stepwise regression (method: backward) to select the best 641 combination of markers that predict the odds of being low T. Bootstrap resampling with 642 replacement method was applied to assess consistency of predictors selected with the stepwise 643 regression. A new variable called Multi Marker Algorithm (MMA) was derived from the predicted 644 log-odds (of being low T) obtained from a binomial logistic regression analysis, in which the 645 dichotomized variable 'testosterone level' (0: normal T (time points A, C) and 1: low T (time point 646 B)) was used as the dependent variable and the intensities of the selected proteins from the stepwise 647 regression were the predictors' variables. Finally, MMA variable was evaluated together with 648 marker candidates proteins. Subsequently, an ROC analysis was performed based on the predicted 649 values and the Younden index method (12) was used to select the optimal cut-off point for the 650 sensitivity and specificity of each marker. All analyses described in this part were performed in R

It is made available under a CC-BY 4.0 International license .

651 software and plotted using ggroc{pROC} function.

652 <u>Background characteristics of the infertile cohort of patients</u>

- 653 To describe background characteristics of the infertile cohort of patients (**Table 1a**), the mean and
- 654 standard deviation (SD) was calculated for variables that followed a normal distribution or the
- 655 median and minimum-maximum (min-max) for variables that were not normally distributed (non-
- 656 Gaussian). The normal distribution was checked by applying a Kolmogorov-Smirnov test.

657 *Testing of the candidate biomarkers in infertile men*

To further perform statistical analyses, the quantified intensities of the candidate biomarkers in infertile men were Log2 transformed to achieve normal distributions. Markers selected from the stepwise regression in the healthy human model were also considered in this cohort to create the MMA variable. In this case, MMA was created to predict the odds of suffering low T or other medical conditions associated with low T levels. Unless other software is specified, the statistical analyzes described in the next steps were performed using R software (2,3).

664 *Distinguishing infertile men with different testosterone levels*

In order to know if the change in the proteins occur with the change in T as observed in the healthy human model, we created three groups of patients based on total T concentration values commonly described in clinical guidelines (13) to define T deficiency: Group 1 contains patients commonly defined with low T (LT): $\leq 8 \text{ nmol/L}$ (n = 22), Group 2 contains patients defined with borderline low T (BL_T): between 8 and 12 nmol/L (n=17), and Group 3 contains patients with normal T (NT): > 12 nmol/L (n = 36). Differences among the three groups of patients were detected by

doing a one-way ANOVA per protein (outcome variable: protein intensity) followed by a pairwise analysis that was corrected to control the FDR provoked by multiple pairwise comparisons (Twostage linear step-up procedure of Benjamini, Krieger and Yekutieli (14), performed in GraphPad Prism software, version 9.00 for Windows, CA, USA). Adjusted p-values < 0.05 were considered significant. An ROC analysis was performed to discriminate the patients with LT from those with BL_T or NT. The same analysis was repeated after excluding the BL_T patients as this group includes males in the gray zone for hypogonadism diagnosis (15–17).

678 *Distinguishing between men with abnormal cardio-metabolic parameters or reduced bone mineral* 679 <u>density</u>

In order to evaluate the diagnostic value of our new protein markers in relation to conditions associated with low T levels, we performed a ROC analysis to discriminate patients with MetS, IR, CVRLP, DM or LBD within the patient cohort using the expression level of the candidate biomarkers and T. Based on the ROC curves, the DeLong's test (paired) was applied in R (roc.test {pROC} function) to compare the AUCs of the candidate biomarkers vs the AUC of T levels to discriminate the above mentioned pathological conditions.

686 Association with Androgen receptor CAG-repeat length

To investigate the androgenic dependence of the levels of the newly defined protein markers, we looked for associations between CAG repeat length and concentration of those markers. The infertile cohort was separated into three groups based on CAG repeat length of the androgen receptor (AR); a group of patients with CAG repeat length 21 and 22 (n=18) was defined as reference group (18–21). Patients with CAG repeat length less than the reference group (< 21)

692	were	included in a group (n=26) and patients with CAG repeat length longer than the reference			
693	group (>22) made up the third group (n=30). Using the softwere GraphPad Prism version 9.0.0 for				
694	Windows (CA, USA), a one-way ANOVA followed by a pairwise test (two-stage linear step-up				
695	procedure of Benjamini, Krieger and Yekutieli (14)) which controls FDR for multiple pairwise				
696	comparison was conducted and adjusted p-values < 0.05 were considered significant.				
697	<u>Refere</u>	ences (Supplementary statistics)			
698	1.	Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, et al. The Perseus			
699		computational platform for comprehensive analysis of (prote)omics data [Internet]. Vol. 13,			
700		Nature Methods. Nature Publishing Group; 2016 [cited 2020 Nov 20]. p. 731-40. Available			
701		from: https://pubmed.ncbi.nlm.nih.gov/27348712/			
702	2.	RStudio Team. RStudio: Integrated Development for R. RStudio. Boston; 2016.			

703 3. Team RC. R: A language and environment for statistical computing. R Foundation for 704 Statistical Computing. 2016.

705 Sahlin KB, Pla I, Sanchez A, Pawłowski K, Leijonhufvud I, Appelqvist R, et al. Short-term 4. 706 effect of pharmacologically induced alterations in testosterone levels on common blood 707 biomarkers in a controlled healthy human model. Scand J Clin Lab Invest. 2019 Nov;1–7.

708 5. Marshall KW, Mohr S, Khettabi F El, Nossova N, Chao S, Bao W, et al. A blood-based 709 biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer [Internet]. 710 2009 Mar 1 [cited] 2020 Nov 20];126(5):NA-NA. Available from: 711 http://doi.wiley.com/10.1002/ijc.24910

712	6.	Bowers AJ, Zhou X. Receiver Operating Characteristic (ROC) Area Under the Curve
713		(AUC): A Diagnostic Measure for Evaluating the Accurate	cy of Predictors of Education
714		Outcomes. J Educ Students Placed Risk [Internet]. 20	019 Jan 2 [cited 2020 Nov
715		20];24(1):20–46. Available	from:
716		https://www.tandfonline.com/doi/abs/10.1080/10824669.20	18.1523734
717	7.	Šimundić A-M. Measures of diagnostic accuracy: basic defin	nitions.
718	8.	Kim MS, Pinto SM, Getnet D, Nirujogi RS, Manda SS, Cha	erkady R, et al. A draft map of
719		the human proteome. Nature [Internet]. 2014 [cited 202	20 Dec 4];509(7502):575-81.
720		Available from: https://pubmed.ncbi.nlm.nih.gov/24870542/	/
721	9.	Kampf C, Mardinoglu A, Fagerberg L, Hallström BM, Edle	und K, Lundberg E, et al. The
722		human liver-specific proteome defined by transcriptomics	and antibody-based profiling.
723		FASEB J [Internet]. 2014 Jul 1 [cited 2021 Apr 29];28	(7):2901–14. Available from:
724		https://pubmed.ncbi.nlm.nih.gov/24648543/	
725	10.	Kholodenko I V, Yarygin KN. Cellular Mechanisms of Live	r Regeneration and Cell-Based
726		Therapies of Liver Diseases. 2017;	
727	11.	Schmucker DL, Sanchez H. Liver Regeneration and Aging	: A Current Perspective. Curr
728		Gerontol Geriatr Res. 2011;2011.	
729	12.	Youden WJ. Index for rating diagnostic tests. Cancer [Interne	et]. 1950 Jan 1 [cited 2020 Nov
730		20];3(1):32–5. Available	from:
731		https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/	1097-

It is made available under a CC-BY 4.0 International license .

732 0142%281950%293%3A1%3C32%3A%3AAID-CNCR2820030106%3E3.0.CO%3B2-3

733	13.	Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency
734		[Internet]. Vol. 37, Frontiers of Hormone Research. Front Horm Res; 2009 [cited 2020 Nov
735		19]. p. 5–20. Available from: https://pubmed.ncbi.nlm.nih.gov/19011285/
736	14.	Benjamini Y, Krieger AM, Yekutieli D. Adaptive linear step-up procedures that control the
737		false discovery rate. Biometrika. 2006 Sep;93(3):491–507.
738	15.	Chan I, Fui MN, Zajac J, Grossmann M. Assessment and management of male androgen
739		disorders: an update - PubMed [Internet]. Aust Fam Physician. [cited 2020 Nov 20].
740		Available from: https://pubmed.ncbi.nlm.nih.gov/24791767/
741	16.	Lunenfeld B, Arver S, Moncada I, Rees DA, Schulte HM. How to help the aging male?
742		Current approaches to hypogonadism in primary care [Internet]. Vol. 15, Aging Male.
743		Aging Male; 2012 [cited 2020 Nov 20]. p. 187–97. Available from:
744		https://pubmed.ncbi.nlm.nih.gov/23067307/
745	17.	Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks
746		with serum testosterone in older men. J Clin Endocrinol Metab [Internet]. 2006 [cited 2020
747		Nov 20];91(11):4335–43. Available from: https://pubmed.ncbi.nlm.nih.gov/16926258/
748	18.	Casella R, Maduro MR, Lipshultz LI, Lamb DJ. Significance of the polyglutamine tract
749		polymorphism in the androgen receptor. Urology. 2001;58(5):651–6.
750	19.	Stanworth RD, Kapoor D, Channer KS, Jones TH. Androgen receptor CAG repeat

It is made available under a CC-BY 4.0 International license .

751	polymorphism is associated with serum testosterone levels, obesity and serum leptin in men
752	with type 2 diabetes. Eur J Endocrinol. 2008;159(6):739–46.

- 753 20. Kim JW, Bae YD, Ahn ST, Kim JW, Kim JJ, Moon DG. Androgen Receptor CAG Repeat
- 754 Length as a Risk Factor of Late-Onset Hypogonadism in a Korean Male Population. Sex
- 755 Med [Internet]. 2018;6(3):203–9. Available from:
- 756 https://doi.org/10.1016/j.esxm.2018.04.002
- 757 21. Ferlin A, Bartoloni L, Rizzo G, Roverato A, Garolla A, Foresta C. Androgen receptor gene
- CAG and GGC repeat lengths in idiopathic male infertility. Mol Hum Reprod.
 2004;10(6):417–21.

It is made available under a CC-BY 4.0 International license .

Supplementary Figure

Fig. S1. Boxplots based on the Log2 intensities of the differenciatlly expressed proteins. The

healthy human model (i.e. castrated men).



It is made available under a CC-BY 4.0 International license .



It is made available under a CC-BY 4.0 International license .

763 Supplementary tables

Table S1. Metabolic syndrome criteria (NCEP, 2002)				
	NCEP-ATP III			
Hypertension	Systolic BP \geq 130 mmHg and diastolic BP \geq 85 mmHg or antihypertensive treat			
Obesity	Waist circumference ≥102 cm			
Insulin resistance	Fasting P-Glucose ≥ 6.1 mmol/L or treatment for DM			
Dyslipidemia	P-HDL-cholesterol <1.0 mmol/L or statin usage			
Hypertriglyceridemia	Fasting P-Triglycerides $\geq 1.7 \text{ mmol/L}$			
Metabolic syndrome	≥3 criteria			
NCEP-ATP III, National Cholesterol Education Program Adult Treatment Panel III 2002; BP, blood				
pressure; DM, diabetes mellitus; HDL, high-density lipoprotein.				
Supplemental references				
NCEP. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection,				
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.				

Circulation 2002;

It is made available under a CC-BY 4.0 International license .

* bootstrap Coefficient Interval (CI)													
		ROO					post hoc paired t-test						
		AUC (%)		Log2.FC	Log2.FC	Log2.FC		adj.p	adj.p	adj.p	significant		
#	Analyt -	[95% CI]* -	p-value 👻	(B-A] •	(C-B) -	(C-A) •	ANOVA p.val 💌	(B - A) •	(B-C) -	(A-C) -	changes 💌	Sensitivity	Specificity
1	4HPPD	87 [77;96]	0.00000265	0.933	-1.253	-0.319	0.0000008	0.0010467	0.0000316	0.0225833	A-B; B-C; A-C;	85	82
2	IGFBP6	84 [75;91]	0.00000020	-0.511	0.748	0.237	0.0000000	0.0000188	0.0000002	0.0214264	B-C; A-C;A-B;	97	66
3	ALDOB	75 [63;86]	0.00011329	0.603	-0.658	-0.055	0.0000142	0.0007867	0.0003664	0.9998779	A-B; B-C;	73	67
4	MINPP1	80	0.00000261	-0.513	0.770	0.257	0.0000044	0.0014091	0.0000121	0.0948021	A-B; B-C;		
5	PI16	76	0.00004969	-0.347	0.446	0.099	0.0000002	0.0005094	0.0000089	0.0603732	A-B; B-C;		
6	IGFBP2	74	0.00019011	-0.640	1.185	0.545	0.0000000	0.0019273	0.0000000	0.0012160	A-B; B-C; A-C;		
7	THBS4	74	0.00027500	-0.478	0.381	-0.097	0.0026760	0.0062151	0.0062151	0.5141803	A-B; B-C;		
8	PGLYRP2	73	0.00030386	-0.247	0.226	-0.020	0.0001658	0.0004491	0.0004491	0.7698965	A-B; B-C;		
9	COL6A1	73	0.00046401	-0.655	0.403	-0.252	0.0005029	0.0004095	0.0283727	0.1351927	A-B; B-C;		
10	CNDP1	73	0.00051078	0.336	-0.660	-0.324	0.0000172	0.0223163	0.0000401	0.0090046	A-B; B-C; A-C;		
11	SERPINF1	73	0.00052732	-0.206	0.194	-0.012	0.0000030	0.0000539	0.0001855	0.7517160	A-B; B-C;		
12	HYOU1	72	0.00072252	-0.552	0.508	-0.043	0.0040436	0.0043378	0.0174434	0.8124464	A-B; B-C;		
13	FSTL1	71	0.00181638	-0.672	1.130	0.458	0.0042720	0.0313565	0.0237510	0.1408092	A-B; B-C;		
14	FETUB	71	0.00104480	0.235	-0.393	-0.158	0.0005134	0.0472545	0.0003591	0.0964466	A-B; B-C;		
15	F9	71	0.00141005	-0.112	0.287	0.176	0.0000028	0.0355388	0.0000087	0.0036811	A-B; B-C; A-C;		
16	CFD	70	0.00173224	-0.238	0.375	0.137	0.0001221	0.0142391	0.0000846	0.1215239	A-B; B-C;		
17	C1S	69	0.00371295	-0.170	0.123	-0.047	0.0006948	0.0002338	0.0137485	0.3332313	A-B; B-C;		
18	VASN	68	0.00473487	-0.229	0.226	-0.003	0.0037176	0.0065467	0.0065467	0.9715587	A-B; B-C;		
19	COL1A1	68	0.00578005	-0.711	0.540	-0.172	0.0011780	0.0073810	0.0074089	0.3411692	A-B; B-C;		
20	APOF	67	0.00838313	-0.273	0.269	-0.004	0.0078117	0.0094437	0.0094437	0.9747496	A-B; B-C;		
21	SOD3	67	0.00859700	-0.356	0.321	-0.034	0.0074186	0.0185355	0.0101178	0.7844501	A-B; B-C;		
22	COL18A1	67	0.00881574	-0.521	0.381	-0.140	0.0105982	0.0204482	0.0299038	0.4457830	A-B; B-C;		
23	SERPINA6	67	0.00974125	0.241	-0.277	-0.036	0.0155489	0.0216347	0.0216347	0.7296250	A-B; B-C;		
24	APOE	66	0.01506488	0.216	-0.217	-0.002	0.0079678	0.0216084	0.0216084	0.9821841	A-B; B-C;		
25	RNASE1	65	0.02036546	-0.286	0.258	-0.028	0.0399674	0.0382668	0.0382055	0.8438576	A-B; B-C;		
26	GPLD1	65	0.02179807	-0.214	0.178	-0.036	0.0067828	0.0190366	0.0232320	0.5912440	A-B; B-C;		
27	CO6	64	0.03599301	0.196	-0.163	0.033	0.0254637	0.0260492	0.0471678	0.5009590	A-B; B-C;		
28	APOL1	63	0.04338613	0.30	-0.40	-0.10	0.0074690	0.0330538	0.0188492	0.4331313	A-B; B-C;		
29	OLFM1	62	0.06086609	-0.344	0.260	-0.084	0.0053622	0.0187015	0.0276303	0.3909882	A-B; B-C;		
30	PROCR	62	0.06205427	-0.282	0.375	0.093	0.0001748	0.0064107	0.0029897	0.1488471	A-B; B-C;		
31	HRG	62	0.07226674	-0.138	0.159	0.021	0.0072758	0.0292888	0.0215359	0.6555564	A-B; B-C;		

Table S2. Significant proteins selected in the healthy human model from Step 1 and 2.

765